drugset / Trial / NCT06993480
A Study to Evaluate the Antiviral Activity and Immune Response of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)
NaSingle-groupOpen-labelTreatment
Summary
AB-10-8005 is a single-center, open-label Phase II clinical study to evaluate the antiviral activity and immune responses of AHB-137 injection in participants with CHB treated with nucleos (t) ide analogues.
Timeline
- Start
- 2025-07-15
- Primary completion
- 2026-07-17
- Completion
- 2027-02-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AHB-137 | Antisense oligonucleotide | 300 mg | Subcutaneous |